Have you or your loved ones been diagnosed with memory complaint?

You may be eligible to participate in a memory complaint clinical trial.

Have you or your loved ones been diagnosed with memory complaint? You may be eligible to participate in a memory complaint clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Memory Complaint Clinical Trial in Tours
NCT02062099 | Phase 1 | Interventional

Have you or your loved ones been diagnosed with memory complaint?

You may be eligible to participate in a memory complaint clinical trial.

Have you or your loved ones been diagnosed with memory complaint? You may be eligible to participate in a memory complaint clinical trial.

Completed

Male & Female

60 - 80

Years old

This study has recruited 25 Participants

Alzheimer's disease (AD) is the most common cause of dementia in elderly subjects. AD is characterized by brain lesions like extracellular deposits of ß-amyloïd proteins in senile plaques and intracellular neurofibrillary tangles of hyper-phosphorylated tau protein, both of which are associated with the loss of neurons. The development of disease biomarkers for AD (Tau, PhTau and βamyloid dosing in the cerebrospinal fluid, brain MRI, amyloid PET imaging and fluorodeoxyglucose PET imaging) to identify the pathophysiological processes underlying cognitive impairment biomarkers, have been incorporated into revised diagnosis guidelines. Post-mortem human AD and AD animal model studies have reported inflammatory processes also implicated in the neuropathology of AD, and upregulated levels of pro-inflammatory cytokines. In vivo visualization of microglial activation has become possible with the development of molecular imaging ligands (tracers) for use with positron emission tomography (PET). The translocator protein (TSPO) formerly known as the peripheral benzodiazepine receptor (PBR), a receptor located in the outer membrane of mitochondria, is upregulated during neuroinflammation. So targeting TSPO with radiolabeled ligands for PET is considered as an attractive biomarker for neuroinflammation. The main aim of this pilot study is to quantify neuroinflammation, in terms of fixation and distribution of [18F] DPA-714(Binding Potential BP), and to study its relationship with amyloid load, measured with in [18F]AV-45 (Standard Uptake Values ratio) in cognitive decline.